DT-101 vs Osavampator
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: AMPA receptor (positive allosteric modulator) · full Major Depressive Disorder pipeline
DT-101
Developed by Draig Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07610473 (registry estimate)
No aligned efficacy figure on record for this race.
Osavampator
Developed by Neurocrine Biosciences and partners
NCT05203341 · Phase 2 · completed
SAVITRI was a randomized, double-blind, placebo-controlled dose-finding trial in 183 adults with major depressive disorder and an inadequate response to current antidepressant treatment, testing two once-daily doses of osavampator against placebo. The primary endpoint was the change in MADRS total score at Day 28. The sponsor reports that the study met its primary endpoint: one dose improved MADRS by 4.3 points more than placebo (p = 0.0159), while the other dose showed a smaller, non-significant difference of 3.0 points (p = 0.0873). Only one of the two doses was significant. These figures are from the company's topline press release of 23 April 2024 and have not been peer reviewed or posted on ClinicalTrials.gov.
Result from the sponsor's press release or a wire copy of it; no peer-reviewed publication or posted registry results were found.
Next expected readout: July 2027 · NCT06786624 (registry estimate)
Reported efficacy
Change from Baseline in Total Montgomery Åsberg Depression Rating Scale (MADRS) Score at Day 28 (Baseline, Day 28): MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082). (met)
Result source: NCT05203341
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | DT-101 | Osavampator |
|---|---|---|
| MADRS, change (acute) | —Not reported | —Trial running · NCT07196501 |
| CGI-S, change (acute) | —Not reported | —Trial running · NCT07196501 |
| MADRS response | —Not reported | —Trial running · NCT07196501 |
| MADRS remission | —Not reported | —Trial running · NCT07196501 |
| Relapse (% of patients) | —Not reported | —Trial running · NCT07196501 |
MADRS, change (acute)
- DT-101
- —Not reported
- Osavampator
- —Trial running · NCT07196501
CGI-S, change (acute)
- DT-101
- —Not reported
- Osavampator
- —Trial running · NCT07196501
MADRS response
- DT-101
- —Not reported
- Osavampator
- —Trial running · NCT07196501
MADRS remission
- DT-101
- —Not reported
- Osavampator
- —Trial running · NCT07196501
Relapse (% of patients)
- DT-101
- —Not reported
- Osavampator
- —Trial running · NCT07196501
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
DT-101: no structured comparison results are available for Major Depressive Disorder.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DT-101's landscape · Osavampator's landscape